Double radiation attack: could a Drug-Radiation combo stop prostate cancer spread?

NCT ID NCT05079698

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether combining a radioactive drug (177Lu-PSMA-617) with precise radiation therapy (SBRT) is safe for men with hormone-sensitive prostate cancer that has spread to a few other spots in the body. The drug seeks out and attacks cancer cells, while the radiation targets remaining tumors. The main goal is to check for side effects, not yet to measure how well it works. About 29 men will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells) and stereotactic body radiotherapy (SBRT, a precise type of radiation)
What this could lead to: If this combination proves safe, it could offer a new way to delay cancer spread in men with early metastatic prostate cancer.
What could go wrong: This is a very early (Phase 1) safety study with only 29 participants, so it is not designed to prove effectiveness. The treatment involves radiation and may cause side effects like fatigue or bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE SENSITIVE OLIGOMETASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.